CODX Company Profile and Key Details

Q: Who are the executives of CODX?

Mr. Reed L. BensonGen. CounselDr. Brent C. Satterfield Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Mark Poritz Ph.D.Chief Scientific OfficerMr. Andrew BensonHead of Investor RelationsMr. Cameron GundryHead of Commercialization LATAM/EURMr. Dwight H. EganChairman, Chief Executive Officer & PresMr. Brian L. Brown CPAChief Financial Officer & Company Sec.Mr. Dan Bohrer CPAVice President of Fin. & AccountingDr. Mayuranki AlmaulaSenior Vice President of Overseas Operations & Strategic AlliancesMr. Brian L. Brown C.P.A.Chief Financial Officer & Company Sec.

NASDAQ : CODX

Co-Diagnostics

$2.61

At Close 4:00 PM

64.55

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Co-Diagnostics, Inc. (CODX) stock remained unchanged at $2.61 a share on NASDAQ. The stock opened at $2.60, fluctuating between $2.50 to $2.65 during the session.

Stock Snapshot

2.61

Prev. Close

2.91M

Market Cap

2.5

Day Low

-0.1

P/E Ratio

-25.44

EPS (TTM)

-0.75

Cash Flow per Share

2.6

Open

1.12M

Number of Shares

2.65

Day High

93.27%

Free Float in %

2.75

Book Value

108.78K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	2.59	2.65	2.47	2.61	109.88K
Jul 10, 2026	2.68	2.70	2.55	2.61	73.62K
Jul 09, 2026	2.61	2.78	2.60	2.64	135.39K
Jul 08, 2026	2.61	2.71	2.54	2.64	157.8K
Jul 07, 2026	2.69	2.74	2.57	2.71	226.95K
Jul 06, 2026	3.03	3.09	2.70	2.73	505.46K
Jul 02, 2026	3.01	3.40	2.93	2.99	991.36K
Jul 01, 2026	3.30	4.60	2.71	3.08	6.76M
Jun 30, 2026	2.95	3.19	2.95	3.10	155.44K
Jun 29, 2026	3.02	3.19	2.96	2.98	171.37K
Jun 26, 2026	3.08	3.24	3.00	3.06	101.6K
Jun 25, 2026	3.52	3.52	3.02	3.05	221.86K
Jun 24, 2026	3.20	3.75	3.19	3.57	972.67K
Jun 23, 2026	3.03	3.51	2.97	3.23	338.7K
Jun 22, 2026	3.23	3.33	3.11	3.12	170.56K
Jun 18, 2026	3.26	3.44	3.10	3.37	616.19K
Jun 17, 2026	3.73	3.82	2.95	3.33	471.26K
Jun 16, 2026	3.78	3.97	3.41	3.84	349.66K
Jun 15, 2026	3.95	4.17	3.71	3.78	356.37K
Jun 12, 2026	4.70	4.98	3.68	4.29	434.22K

Contact Details

Salt Lake City, UT 84109

United States

https://co-dx.com 801 438 1036

About Company

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Company Overview

The stock is currently mid-range between its 52-week high and low $1.26 and $46.50. With a market capitalization of about $2.91 million, Co-Diagnostics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.85). Key stats such as the average daily volume over the past year has been around 5.88 million shares, volume is running light vs its 52-week average. Headquartered in Salt Lake City, UT, Co-Diagnostics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dwight Egan, the company employs approximately 115 people and listed since July 12, 2017. Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -63.67%, SMA50 -74.34%, SMA200 -75.6%). The stock’s 14-day RSI is 23.23 (weak momentum), while the ATR of 1.12 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -94.92% below its high and over 0.0% above its low. Average 10-day trading volume of 201.52 thousand shares is below the 3-month average of 5.87 million, indicating normal recent market interest.

Valuation Metrics

Co-Diagnostics, Inc. trades at a P/E ratio of -0.08, slightly below the S&P 500 average, with a price-to-sales ratio of 4.1 and a price-to-book ratio of 0.37 suggesting the stock is closer to book value. The P/FCF stands at -0.1, also above market averages.

Dividend & Fair Value

Co-Diagnostics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.86. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Co-Diagnostics, Inc. generated EPS of -$28.73 over the past year. Five-year average earnings growth is -27.4%. Wall Street analysts project EPS growth of 31.42% annually over the next five years. The latest quarter delivered EPS of -$4.06. The next quarter is forecast at -$3.60. Next year's EPS is expected at -$11.11. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $1.50. The high target offers 283.14% upside. The low target suggests -42.53% downside. The mean target is $5.08. This offers 94.64% upside. Co-Diagnostics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 8.27%. The prior quarter beat by 354.17%. Over the last six quarters, Apple has recorded several small beats. These include 5.88% in March 27, 2025.

Shareholding & Insider Activity

Co-Diagnostics, Inc. has 38.52 million shares outstanding. The public float is 35.89 million shares, elevated short interest at 3.79% of float. This equals 1.36 million shares. The short ratio is 0.3 days. Institutional investors hold 14.61% of the float. Insiders own 7.88%. Satterfield Brent holds 2.28 million shares, Brown Brian Lee has 76.24 thousand shares and SERBIN RICHARD S has 2.50 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Co-Diagnostics generated $991.47K in revenue, or $0.03 per share. Gross margin was -446.20%, operating margin -4894.41%, and net profit margin -3563.67%. Returns are negative, with ROA at -34.09% and ROE at -41.08%.
On valuation metrics, Co-Diagnostics trades at a P/E of -0.08, P/S of 4.10 and P/B of 0.37. The current ratio is 2.28 and quick ratio is 2.09. Operationally, the company’s inventory turnover is 0.77 and cash conversion cycle is -616.10 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.13, supported by a cash flow-to-debt ratio of -13.91.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Co-Diagnostics posted revenue of $991.47K, down slightly from $34.22M in the prior quarter. Gross profit was - $4.42M (margin -446.20%). Operating income was - $48.53M (margin -4894.4%). Net income was- $35.33M (EPS - $1.20).
The company ended the quarter with $58.55M in cash and short-term investments, a total debt of $2.99M, and net debt of - $11.93M. Total assets were $103.65M, with equity of $86.01M. Financials further reflected weakness, with operating cash flow of - $22.08M, free cash flow of - $23.45M, and capital expenditures of - $1.37M.

Price Forecast & Outlook

Our AI price prediction model suggests that Co-Diagnostics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -56.7%, with price expected at $1.13 by July 27, 2026, within a range of $0.00 to $3.08 3-Month Outlook: Projected rise of 449.81%, reaching $14.35 by October 08, 2026, with a range of $14.13 to $14.59. 1-Year Outlook: Projected gain of 184.29%, with price at $7.42 by July 13, 2027, within a range of $7.29 to $7.65.

Key Takeaways

Co-Diagnostics, Inc. (NASDAQ:CODX) shares are up 1578.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Co-Diagnostics, Inc. trading at a premium to the broader market with a P/E of -0.08. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.19, suggesting 175.48% upside. Our AI forecast model points to short-term weakness (-56.7% over two weeks), a medium-term rise (449.81% over three months), and a longer-term gain (184.29% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Co-Diagnostics, Inc. (CODX) stock price?

Co-Diagnostics, Inc. (NASDAQ: CODX) stock price is $2.61 in the last trading session. During the trading session, CODX stock reached the peak price of $2.65 while $2.50 was the lowest point it dropped to. The percentage change in CODX stock occurred in the recent session was 0% while the dollar amount for the price change in CODX stock was $0.00.

CODX's industry and sector of operation?

The NASDAQ listed CODX is part of Biotechnology industry that operates in the broader Healthcare sector. Co-Diagnostics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CODX?

Mr. Reed L. Benson
Gen. Counsel
Dr. Brent C. Satterfield Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Mark Poritz Ph.D.
Chief Scientific Officer
Mr. Andrew Benson
Head of Investor Relations
Mr. Cameron Gundry
Head of Commercialization LATAM/EUR
Mr. Dwight H. Egan
Chairman, Chief Executive Officer & Pres
Mr. Brian L. Brown CPA
Chief Financial Officer & Company Sec.
Mr. Dan Bohrer CPA
Vice President of Fin. & Accounting
Dr. Mayuranki Almaula
Senior Vice President of Overseas Operations & Strategic Alliances
Mr. Brian L. Brown C.P.A.
Chief Financial Officer & Company Sec.

How CODX did perform over past 52-week?

CODX's closing price is 107.14% higher than its 52-week low of $1.26 where as its distance from 52-week high of $46.50 is -94.39%.

How many employees does CODX have?

Number of CODX employees currently stands at 112.

Link for CODX official website?

Official Website of CODX is: https://co-dx.com

How do I contact CODX?

CODX could be contacted at phone 801 438 1036 and can also be accessed through its website. CODX operates from 2401 S. Foothill Dr., Salt Lake City, UT 84109, United States.

How many shares of CODX are traded daily?

CODX stock volume for the day was 108.78K shares. The average number of CODX shares traded daily for last 3 months was 5.88M.

What is the market cap of CODX currently?

The market value of CODX currently stands at $2.91M with its latest stock price at $2.61 and 1.12M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	112
Beta	2.85
Sales or Revenue	$991.47K
5Y Sales Change%	71.611%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CODX Company Profile and Key Details

Co-Diagnostics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics